🆕💫Retrospective study
Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim sulfa (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study #idxposts@DrToddLee https://t.co/AFFKEWLrKj
How do clinicians make decisions about suppressive antibiotic therapy for patients who had prosthetic joint infections (PJIs) when there is limited evidence about benefits and risks?
🆕💫Qualitative study
https://t.co/j80pQwqzxN
Impact of VRE-active perioperative prophylaxis in liver transplant patients colonized by Vancomycin-Resistant Enterococci
✅ Just Accepted
https://t.co/r7pnyiElJL
For a long time we have inappropriately been giving abx for liver pts. Here are yet more data. Practice will be changing and more is to come on this. But GI investigators, stop looking at UTIs. They are usually misdiagnosed. Focus on more accurate Dx.
Blood culture-negative endocarditis (BCNE)
Causes of BCNE:
1. Previous Antibiotic Use:
The most common cause of BCNE is the administration of antibiotics before blood cultures are taken, which can suppress bacterial growth in the blood.
5 years on from lockdown and history has been rewritten.
I'm here to remind you what actually happened.
For example ;
Hospitals in London ran out of oxygen to give to patients, such was the flood of patients with respiratory failure resulting from Covid.
Deciphering Positive Cytomegalovirus IgM Test Information in Immunocompetent Adults Hospitalized with Illness Suspicious for Acute Cytomegalovirus Infection: A Multihospital Observational Study
✅ Just Accepted
🔗 https://t.co/7oWvQTlo4b
Making mRNA a dirty word is sadly one of the greatest achievements of the anti science anti vaccine movement.
In reality mRNA vaccines are scientific genius and an amazing breakthrough.
Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials
https://t.co/f5Qccm8jws
Top 5 advances in medical science this week (🧵)
1. Potential for year-long HIV protection in one dose
Lenacapavir prevents HIV with 99.9-100% efficacy when given twice per year - this is a new formulation that allows it to be given just once per year
Lenacapavir is not a vaccine - it's a long-acting anti-retroviral that stops HIV from establishing infection
This is a phase 1 trial, so there’s no efficacy data, but the drug's plasma concentration stayed at higher levels than the 6-monthly formulation that achieved ≥99.9% efficacy, without safety concerns
The dose needs to be optimised, and it has to progress further through trials, but this has potential to expand access to an extremely effective tool for HIV prevention
https://t.co/APqlWFbsCy
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials
✅ Just Accepted
https://t.co/B47tC1S9Lr
🆕💫Impact of tebipenem pivoxil on the intestinal microbiota and on establishment of colonization with carbapenem-resistant Klebsiella pneumoniae in mice #IDXposts
https://t.co/2gOFzkhnWE
#IDtwitter#IDXpost this is something I have been worried for a while. My micro lab does not usually test for ertapenem R and most extrapolate susceptibility from meropenem and prefer to use Erta for OPAT because is more convenient @BradSpellberg@DrToddLee@ABsteward@wwrighID